O_06 - Longitudinal changes in FIB-4 and improvement in fibrosis stage with obeticholic acid: A secondary analysis of FLINT Trial | Dr. A. Sanyal

International Workshop on NASH Biomarkers 2016

Need for Biomarker Development in Non-Alcoholic Fatty Liver Disease | Eric Lefebvre, MD

International Workshop on NASH Biomarkers 2016

Principles of Biomarker Development | Margery Connelly, PhD, MBA

International Workshop on NASH Biomarkers 2016

Quantitative measures of liver health | Grey Everson, MD

International Workshop on NASH Biomarkers 2016

Defining the gold standard in Biomarker Validation in NAFLD | Arun Sanyal, MD, MBBS

International Workshop on NASH Biomarkers 2016

O_02 - Performance of non-invasive tests in the staging of fibrosis in patients with NAFLD: interim results of a prospective multicentre study | Dr. P. Eddowes

International Workshop on NASH Biomarkers 2016

Biomarkers: what can be learned from type 2 diabetes | Manu Chakravarthy, MD, PhD

International Workshop on NASH Biomarkers 2016

Proteomics-based biomarker discovery in NAFLD | Naga Chalasani, MD

International Workshop on NASH Biomarkers 2016

Study Design and endpoints in Omics-based biomarker studies | Stephen Williams, MD, PhD

International Workshop on NASH Biomarkers 2016

Lipid and Bile acids as NAFLD-related biomarkers | Puneet Puri, MBBS, MD

International Workshop on NASH Biomarkers 2016

Potential approach to identify the NAFLD patient who will develop HCC | Yujin Hoshida, MD, PhD

International Workshop on NASH Biomarkers 2016

Simple laboratory based indices | Ray Kim, MD

International Workshop on NASH Biomarkers 2016

Biomarker development in pediatric NAFLD: special challenges in a special population | Saul Karpen, MD, PhD

International Workshop on NASH Biomarkers 2016

Dynamic measurement of physiologic functions: any role in NASH diagnostics | Stephen Previs, MD

International Workshop on NASH Biomarkers 2016

Microbiome: diagnostic considerations | Patrick Gillevet

International Workshop on NASH Biomarkers 2016

O_03 - A non-invasive lipidomic test accurately discriminates NASH from steatosis: a blind validation study | Dr. T. Montgomery

International Workshop on NASH Biomarkers 2016

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Management of DAA Failures - Gregory T. Everson, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Who Should We Treat? What is the “Point-of-No-Return”? - Norah Terrault, MD, MPH, FAASLD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Treatment Experienced GT3 patient with Cirrhosis - Geoffrey McCaughan, MD, PhD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Is Treatment Cost-effective? - Kosh Agarwal, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

What Are the Treatment Options? - Xavier Forns, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

When to Treat HCV in a Waiting List Patient? - Stefano Fagiuoli, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Achieving SVR in CTP C – MELD Purgatory - Christophe Duvoux, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016